SAN DIEGO--(BUSINESS WIRE)--Somaxon Pharmaceuticals, Inc. (Nasdaq: SOMX), a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products for the treatment of diseases and disorders in the central nervous system therapeutic area, today announced that on March 20, 2009 it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the company that based on the company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the period ended December 31, 2008, the company does not comply with the minimum $10 million stockholders’ equity requirement for continued listing on the Nasdaq Global Market under Nasdaq Marketplace Rule 4450(a)(3).
